Kromek announces its final results for the year ended 30 April 2025

Kromek, a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces its final results for the year ended 30 April 2025.

Financial Highlights:

Revenue increased 37% to £26.5m (2024: £19.4m)
- Advanced Imaging revenue of £20.3m (2024: £9.0m)
- CBRN Detection revenue of £6.2m (2024: £10.4m)
Gross margin improved to 81% (2024: 55%)
Adjusted EBITDA increased to £10.3m (2024: £3.1m)*
Profit before tax was significantly ahead of market expectations at £3.1m (2024: £3.5m loss), which is positive for the first time in the history of Kromek
£5.5m term loan facility and £5.9m short-term loan facilities were repaid in February 2025
Cash and cash equivalents at 30 April 2025 were £1.7m (30 April 2024: £0.5m) with $5m received post year end and an undrawn credit facility of £6.0m plus a £0.5m asset finance facility to ensure there is sufficient capital to drive further growth
*A reconciliation of adjusted EBITDA can be found in the Financial Review